ArticleTobacco control2005
Understanding Philip Morris's pursuit of US government regulation of tobacco.
Article in Tobacco control, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- How does the tobacco industry attempt to influence marketing regulations? A systematic review.PloS one · 2014Pooled it
- The vector of the tobacco epidemic: tobacco industry practices in low and middle-income countries.Cancer causes & control : CCC · 2012Pooled it
- Food as harm reduction during a drinking session: reducing the harm or normalising harmful use of alcohol? A qualitative comparative analysis of alcohol industry and non-alcohol industry-funded guidance.Harm reduction journal · 2022Article
- Revolution or redux? Assessing IQOS through a precursor product.Tobacco control · 2018Article
- Public versus internal conceptions of addiction: An analysis of internal Philip Morris documents.PLoS medicine · 2018Article
- US Media Coverage of Tobacco Industry Corporate Social Responsibility Initiatives.Journal of community health · 2018Article
- Tobacco Industry Research on Nicotine Replacement Therapy: "If Anyone Is Going to Take Away Our Business It Should Be Us".American journal of public health · 2017Article
- Unpacking commercial sector opposition to European smoke-free policy: lack of unity, 'fear of association' and harm reduction debates.Tobacco control · 2016Article
- Tobacco industry use of personal responsibility rhetoric in public relations and litigation: disguising freedom to blame as freedom of choice.American journal of public health · 2015Article
- Old wine in new bottles: tobacco industry's submission to European Commission tobacco product directive public consultation.Health policy (Amsterdam, Netherlands) · 2015Article
- Nonsmokers' responses to new warning labels on smokeless tobacco and electronic cigarettes: an experimental study.BMC public health · 2014Article
- Article
- "The Big WHY": Philip Morris's failed search for corporate social value.American journal of public health · 2012Article
- Corporate image and public health: an analysis of the Philip Morris, Kraft, and Nestlé websites.Journal of health communication · 2012Article
- The toxic effects of cigarette additives. Philip Morris' project mix reconsidered: an analysis of documents released through litigation.PLoS medicine · 2011Article
- Whose butt is it? tobacco industry research about smokers and cigarette butt waste.Tobacco control · 2011Article
- Compromise or capitulation? US Food and Drug Administration jurisdiction over tobacco products.PLoS medicine · 2009Article
- The role of corporate credibility in legitimizing disease promotion.American journal of public health · 2009Article
- "Working to shape what society's expectations of us should be": Philip Morris' societal alignment strategy.Tobacco control · 2008Article
- Corporate philanthropy, lobbying, and public health policy.American journal of public health · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo investigate Philip Morris's support of US Food and Drug Administration (FDA) regulation of tobacco products and analyse its relationship to the company's image enhancement strategies. DATA SOURCES: Internal Philip Morris documents released as part of the Master Settlement Agreement.
methodsSearches of the Legacy Tobacco Documents Library (http://legacy.library.ucsf.edu) beginning with such terms as "FDA" and "regulatory strategy" and expanding to include relevant new terms.
resultsPhilip Morris's support for government regulation of tobacco is part of a broader effort to address its negative public image, which has a damaging impact on the company's stock price, political influence, and employee morale. Through regulation, the company seeks to enhance its legitimacy, redefine itself as socially responsible, and alter the litigation environment. Whereas health advocates frame tobacco use as a public health policy issue, Philip Morris's regulatory efforts focus on framing tobacco use as an individual choice by informed adults to use a risky product. This framing allows Philip Morris to portray itself as a reasonable and responsible manufacturer and marketer of risky products.
conclusionsPhilip Morris's ability to improve its image through support of FDA regulation may undermine tobacco control efforts aimed at delegitimising the tobacco industry. It may also create the impression that Philip Morris's products are being made safer and ultimately protect the company from litigation. While strong regulation of tobacco products and promotion remain critical public health goals, previous experiences with tobacco regulation show that caution may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.